pocketful logo
Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

NSE: AUROPHARMA BSE: 524804

₹1389.50

(-0.52%)

Tue, 05 May 2026, 10:15 pm

Aurobindo Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    79906.69

  • Net Profit

    3483.57

  • P/B

    2.06

  • Sector P/E

    33.38

  • P/E

    19.32

  • EV/EBITDA

    9.39

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    17.01

  • ROCE (Industry)

    16.41

  • RONW (Industry)

    14.52

  • ROE

    11.15

  • ROCE

    14.16

  • Debt/Equity

    0.24

  • EPS (TTM)

    60.80

  • Dividend Yield

    0

  • Book Value

    603.32

  • Interest Cover

    12.08

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (11.4x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
  • Aurobindo Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Aurobindo Pharma's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Aurobindo Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Aurobindo Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Aurobindo Pharma is expected to decrease over the next 2 years.
  • Aurobindo Pharma's earnings are expected to grow by 9.7% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters51.8251.8251.8251.8251.82
FII15.2413.9414.2114.3715.33
DII25.8727.6827.6026.9326.23
Public7.086.556.386.876.61
Government0000.000.00

Read More

Technical Analysis

RSI

64.06

MACD

30.41

50 DMA

1302.63

200 DMA

1180.09

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1758.501565.101477.301371.701283.901178.30984.90
Fibonacci1565.101491.221445.581371.701297.821252.181178.30
Camarilla1442.681424.961407.231371.701371.771354.041336.32

Pivots Level: Classic

R3

+386.80

1758.50

R2

+193.40

1565.10

R1

+105.60

1477.30

1371.70
1371.70
Pivot Point
LTP: 1428.10

S1

-87.80

1283.90

S2

-193.40

1178.30

S3

-386.80

984.90

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1399.88

  • 20-EMA

    1379.54

  • 30-EMA

    1357.40

  • 50-EMA

    1320.99

  • 100-EMA

    1266.39

  • 200-EMA

    1222.55

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
06 Apr 2026buyback
09 Feb 2026board-meetingsQuarterly Results, Nine Months Results
05 Nov 2025board-meetingsQuarterly Results
12 Aug 2025agm
04 Aug 2025dividend₹4.00 Dividend /Share08 Aug 2025
08 Jul 2025dividendInterim Dividend - Rs. - 408 Aug 2025
30 Jul 2024agm
26 Jul 2024agmAnnual General Meeting27 Aug 2024
18 Jul 2024buyback
30 Jun 2024buybackBuy Back of Shares30 Jul 2024

Read More

Peer Comparison

Aurobindo Pharma Ltd logo

Aurobindo Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Aurobindo Pharma Ltd About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1986

Headquarters

CEO

M R Kumar

Employees

Contact

Website icon

Website

http://www.aurobindo.com

Email icon

Email

cs@aurobindo.com; investorgrievances@aurobindo.com

Phone icon

Phone

91-40-23736370

Location icon

Location

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Read More

Aurobindo Pharma Ltd Company History

YearHistory
2020
  • Tied up with BIRAC to develop COVID-19 vaccine.
  • Collaborated with CSIR to develop COVID-19 vaccine.
  • Signed exclusive licensing agreement with COVAXX.
2021
  • Received USFDA approval for Droxidopa Capsules.
  • Received NCLT approval for scheme of amalgamation.
2022
  • Acquired 51% stake in GLS Pharma Limited.
  • Arm received final USFDA approval for Vasopressin injection.
  • Arm received USFDA approval for Triamcinolone Acetonide injectable suspension.
2023
  • Arm received USFDA approval for cancer drug.
  • To launch HIV triple combination product for children under ViiV Healthcare licence.
2024
  • Received first USFDA approval for Lidocaine Hydrochloride Injection.
  • Commissioned four plants in Andhra Pradesh including Pen-G facility.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
SUNEELA RANI PENAKASell8660510849.307 Oct 2016
THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDEBuy2360231875.9419 Sept 2014
ABU DHABI INVESTMENT AUTHORUTY - GULABBuy1475687670.5130 May 2014
M/S MORGAN STANLEY ASIA SINGAPORE PTESell1732500669.9230 May 2014
MACQUARIE BANK LIMITEDSell1940000180.9729 Aug 2013
RELIANCE MUTUAL FUNDBuy1500000172.9924 Feb 2011
MANDATUM INDIA FUNDSell2353228173.0324 Feb 2011
DEUTSCHE SECURITIES MAURITIUS LTD.Buy3757501037.5326 Aug 2010
MERRILL LYNCH CAPITAL MARKETS ESPANA S.A SV FCCBSell7038981035.6626 Aug 2010
DEUTSCHE SECURITIES MAURITIUS LIMITEDBuy597541851.528 Jan 2010

Read More

Aurobindo Pharma Ltd News

Aurobindo Pharma's Apitoria CEO Resigns Effective May 4

Dr. Sanjay Chaturvedi resigns as CEO of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, effective May 4, 2026, to pursue a different opportunity.

04 May 2026

companies

Aurobindo's CuraTeQ Gets Health Canada Nod for Bevqolva

CuraTeQ Biologics, Aurobindo Pharma's subsidiary, receives Health Canada NOC for Bevqolva bevacizumab biosimilar. Product already launched in UK, under EMA review.

02 May 2026

companies

Aurobindo's CuraTeQ Gets Health Canada Nod for Bevqolva

CuraTeQ Biologics, Aurobindo Pharma's subsidiary, receives Health Canada NOC for Bevqolva bevacizumab biosimilar. Product already launched in UK, under EMA review.

01 May 2026

companies

Aurobindo's CuraTeQ Gets Health Canada Nod for Bevqolva

CuraTeQ Biologics, Aurobindo Pharma's subsidiary, receives Health Canada NOC for Bevqolva bevacizumab biosimilar. Product already launched in UK, under EMA review.

01 May 2026

companies

Aurobindo Pharma CBO Emerging Markets Retires

Aurobindo Pharma announces retirement of Mr. N. Ravi Kiran, Chief Business Officer for Emerging Markets, effective April 30, 2026, under SEBI Regulation 30 compliance.

30 Apr 2026

companies

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800